QiShenYiQi pill inhibits atherosclerosis by promoting TTC39B-LXR mediated reverse cholesterol transport in liver
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
QiShenYiQi pill inhibits atherosclerosis by promoting TTC39B-LXR mediated reverse cholesterol transport in liver
Authors
Keywords
-
Journal
PHYTOMEDICINE
Volume -, Issue -, Pages 155192
Publisher
Elsevier BV
Online
2023-11-05
DOI
10.1016/j.phymed.2023.155192
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Attenuating lipid metabolism in atherosclerosis: The potential role of Anti-oxidative effects on low-density lipoprotein of herbal medicines
- (2023) Huxinyue Duan et al. Frontiers in Pharmacology
- QiShenYiQi pill inhibits atherosclerosis by promoting reverse cholesterol transport PPARγ-LXRα/β-ABCA1 pathway
- (2023) Jing Xie et al. JOURNAL OF ETHNOPHARMACOLOGY
- Free Cholesterol Bioavailability and Atherosclerosis
- (2022) Rei J. Abe et al. Current Atherosclerosis Reports
- Gut Microbially Produced Indole-3-Propionic Acid Inhibits Atherosclerosis by Promoting Reverse Cholesterol Transport and Its Deficiency Is Causally Related to Atherosclerotic Cardiovascular Disease
- (2022) Hongliang Xue et al. CIRCULATION RESEARCH
- Establishment and validation of the quantitative analysis of multi‐components by single marker for the quality control of Qishen Yiqi dripping pills by high‐performance liquid chromatography with charged aerosol detection
- (2021) Linlin Wu et al. PHYTOCHEMICAL ANALYSIS
- Canagliflozin Facilitates Reverse Cholesterol Transport Through Activation of AMPK/ABC Transporter Pathway
- (2021) Yingnan Zhao et al. Drug Design Development and Therapy
- Crosstalk Between LXR and Caveolin-1 Signaling Supports Cholesterol Efflux and Anti-Inflammatory Pathways in Macrophages
- (2021) Cristina M. Ramírez et al. Frontiers in Endocrinology
- Mechanistic Insights into the Oxidized Low-Density Lipoprotein-Induced Atherosclerosis
- (2020) Chainika Khatana et al. Oxidative Medicine and Cellular Longevity
- Full-length transcript sequencing and comparative transcriptomic analysis to evaluate the contribution of osmotic and ionic stress components towards salinity tolerance in the roots of cultivated alfalfa (Medicago sativa L.)
- (2019) Dong Luo et al. BMC PLANT BIOLOGY
- HDL and Reverse Cholesterol Transport
- (2019) Mireille Ouimet et al. CIRCULATION RESEARCH
- Low-density lipoprotein cholesterol and risk of intracerebral hemorrhage
- (2019) Chaoran Ma et al. NEUROLOGY
- A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke
- (2019) Pierre Amarenco et al. NEW ENGLAND JOURNAL OF MEDICINE
- Polyphenol Effects on Cholesterol Metabolism via Bile Acid Biosynthesis, CYP7A1: A Review
- (2019) Karen F. Chambers et al. Nutrients
- Ginkgo biloba extracts prevent aortic rupture in angiotensin II-infused hypercholesterolemic mice
- (2018) Xiao-fang Huang et al. ACTA PHARMACOLOGICA SINICA
- SR-B1: A Unique Multifunctional Receptor for Cholesterol Influx and Efflux
- (2018) Wen-Jun Shen et al. Annual Review of Physiology
- Dapsone protects brain microvascular integrity from high-fat diet induced LDL oxidation
- (2018) Rui Zhan et al. Cell Death & Disease
- (–)-Epigallocatechin-3-Gallate Ameliorates Atherosclerosis and Modulates Hepatic Lipid Metabolic Gene Expression in Apolipoprotein E Knockout Mice: Involvement of TTC39B
- (2018) Wei Wang et al. Frontiers in Pharmacology
- The Contribution of Different Components in QiShenYiQi Pills® to Its Potential to Modulate Energy Metabolism in Protection of Ischemic Myocardial Injury
- (2018) Yuan-Chen Cui et al. Frontiers in Physiology
- SR-BI: A Multifunctional Receptor in Cholesterol Homeostasis and Atherosclerosis
- (2017) MacRae F. Linton et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- QiShenYiQi pill attenuates atherosclerosis by promoting regulatory T cells, inhibiting T helper 17 cells and accelerating cholesterol excretion
- (2017) Li Peng et al. Oncotarget
- TTC39B deficiency stabilizes LXR reducing both atherosclerosis and steatohepatitis
- (2016) Joanne Hsieh et al. NATURE
- QiShenYiQi Pills, a compound in Chinese medicine, protects against pressure overload-induced cardiac hypertrophy through a multi-component and multi-target mode
- (2015) Yuan-Yuan Chen et al. Scientific Reports
- A Network Pharmacology Study of Chinese Medicine QiShenYiQi to Reveal Its Underlying Multi-Compound, Multi-Target, Multi-Pathway Mode of Action
- (2014) Xiang Li et al. PLoS One
- Activation of Liver X Receptor Decreases Atherosclerosis in Ldlr −/− Mice in the Absence of ATP-Binding Cassette Transporters A1 and G1 in Myeloid Cells
- (2013) Mojdeh S. Kappus et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Scavenger receptor BI and ABCG5/G8 differentially impact biliary sterol secretion and reverse cholesterol transport in mice
- (2013) Arne Dikkers et al. HEPATOLOGY
- Cholesterol Efflux and Atheroprotection
- (2012) Robert S. Rosenson et al. CIRCULATION
- Progress and challenges in translating the biology of atherosclerosis
- (2011) Peter Libby et al. NATURE
- Liver X Receptor Signaling Pathways and Atherosclerosis
- (2010) Anna C. Calkin et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Global Chemome Study by LC Coupled with DAD and ESI–Q–TOF MS of a Composite Traditional Chinese Medicine Qishenyiqi Dropping Pills
- (2010) Jing Wang et al. CHROMATOGRAPHIA
- A piRNA Pathway Primed by Individual Transposons Is Linked to De Novo DNA Methylation in Mice
- (2008) Alexei A. Aravin et al. MOLECULAR CELL
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started